Meaning of tumor protein 53-induced nuclear protein 1 in the molecular mechanism of gemcitabine sensitivity

Nakaya,Naoki; Ishigaki,Yasuhito; Nakajima,Hideo; Murakami,Manabu; Shimasaki,Takeo; Takata,Takanobu; Ozaki,Mamoru; Dusetti,Nelson  J.; Iovanna,Juan  L.; Motoo,Yoshiharu

doi:10.3892/mco.2012.8

Meaning of tumor protein 53-induced nuclear protein 1 in the molecular mechanism of gemcitabine sensitivity

Authors:
- Naoki Nakaya
- Yasuhito Ishigaki
- Hideo Nakajima
- Manabu Murakami
- Takeo Shimasaki
- Takanobu Takata
- Mamoru Ozaki
- Nelson J. Dusetti
- Juan L. Iovanna
- Yoshiharu Motoo
View Affiliations

Affiliations: Department of Medical Oncology, Kanazawa Medical University, Uchinada, Ishikawa, Japan, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa, Japan, Stress Cellulaire, INSERM U624, Marseille, France
Published online on: August 8, 2012 https://doi.org/10.3892/mco.2012.8
Pages: 100-104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stress proteins of the pancreas, such as tumor protein 53-induced nuclear protein 1 (TP53INP1), are important factors in the invasion and metastasis of pancreatic cancer. TP53INP1 is a pro-apoptotic factor and is transcriptionally regulated in p53-dependent and -independent manners. A previous study proved that gemcitabine induces TP53INP1 expression in pancreatic cancer cells and the pancreatic cancer cell line (PANC-1). The present study aimed to clarify the association between TP53INP1 and gemcitabine sensitivity. The expression of TP53INP1 and its related factors, such as cell growth and cell cycle status in TP53INP1-knockout mouse embryonic fibroblasts [TP53INP1-/--mouse embryonic fibroblasts (MEFs)] to those in wild-type counterparts (TP53INP1+/+-MEFs) were compared. Flow cytometric analysis demonstrated no difference of the checkpoint function in TP53INP1-/-‑MEFs and TP53INP1+/+‑MEFs when exposed to 10 ng/ml of gemcitabine. No significant difference was found in the level of p53 expression in the cell types, although the base level and gemcitabine-induced expression of p21 were significantly decreased in TP53INP1-/-‑MEFs, compared to those in wild-type counterparts. Results showed that gemcitabine induced the p21 expression in TP53INP1+/+-MEFs, although not in TP53INP1-/-‑MEFs. However, their respective cell-cycle checkpoints were not different. Therefore, TP53INP1 was found to be associated with drug sensitivity through control of the cell cycle.

View Figures

View References

1.	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
2.	Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006.
3.	Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? Oncol Rep. 23:1183–1192. 2010.
4.	Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:6110–6117. 1991.
5.	Gandhi V, Mineishi S, Huang P, Yang Y, Chubb S, Chapman AJ, Nowak BJ, Hertel LW and Plunkett W: Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 22:61–67. 1995.
6.	Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 38:567–572. 1990.
7.	Keim V, Iovanna JL and Dagorn JC: The acute phase reaction of the exocrine pancreas. Gene expression and synthesis of pancreatitis-associated proteins. Digestion. 55:65–72. 1994.
8.	Xie MJ, Motoo Y, Iovanna JL, Su SB, Ohtsubo K, Matsubara F and Sawabu N: Overexpression of pancreatitis-associated protein (PAP) in human pancreatic ductal adenocarcinoma. Dig Dis Sci. 48:459–464. 2003.
9.	Motoo Y, Satomura Y, Mouri I, Mouri H, Ohtsubo K, Sakai J, Fujii T, Taga H, Yamaguchi Y, Watanabe H, et al: Serum levels of pancreatitis-associated protein in digestive diseases with special reference to gastrointestinal cancers. Dig Dis Sci. 44:1142–1147. 1999.
10.	Su SB, Motoo Y, Iovanna JL, Xie MJ and Sawabu N: Effect of camostat mesilate on the expression of pancreatitis-associated protein (PAP), p8, and cytokines in rat spontaneous chronic pancreatitis. Pancreas. 23:134–140. 2001.
11.	Nowak J, Tomasini R, Mattei MG, Azizi Samir LA, Dagorn JC, Dusetti N, Iovanna JL and Pébusque MJ: Assignment of tumor protein p53 induced nuclear protein 1 (TP53INP1) gene to human chromosome band 8q22 by in situ hybridization. Cytogenet Genome Res. 97:140E2002.
12.	Tomasini R, Samir AA, Pebusque MJ, Calvo EL, Totaro S, Dagorn JC, Dusetti NJ and Iovanna JL: P53-dependent expression of the stress-induced protein (SIP). Eur J Cell Biol. 81:294–301. 2002.
13.	Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M and Nakamura Y: p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell. 8:85–94. 2001.
14.	Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et al: Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.
15.	Jiang PH, Motoo Y, Sawabu N and Minamoto T: Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol. 12:1597–1602. 2006.
16.	Möller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Dröge W, Will H and Schmitz ML: PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res. 63:4310–4314. 2003.
17.	Yoshida K, Liu H and Miki Y: Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem. 281:5734–5740. 2006.
18.	Gommeaux J, Cano C, Garcia S, Gironella M, Pietri S, Culcasi M, Pébusque MJ, Malissen B, Dusetti N, Iovanna J and Carrier A: Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol. 27:2215–2228. 2007.
19.	Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A and Donehower LA: In vitro growth characteristics of embryo fibro-blasts isolated from p53-deficient mice. Oncology. 8:2457–2467. 1993.
20.	Jiang PH, Motoo Y, Garcia S, Iovanna JL, Pébusque MJ and Sawabu N: Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer. World J Gastroenterol. 12:691–696. 2006.
21.	Cano CE, Gommeaux J, Pietri S, Culcasi M, Garcia S, Seux M, Barelier S, Vasseur S, Spoto RP, Pébusque MJ, et al: Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res. 69:219–226. 2009.
22.	Niculescu AB III, Chen X, Smeets M, Hengst L, Prives C and Reed SI: Effects of p21Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 18:629–643. 1998.
23.	Xia QS, Ishigaki Y, Zhao X, Shimasaki T, Nakajima H, Nakagawa H, Takegami T, Chen ZH and Motoo Y: Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells. Pancreas. 40:55–60. 2011.